Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 5/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | GLB1 | P16278 | 4/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256046 | 0.94 | CYP1A2 (0.35) | CYP1A2ALDH1A1GBA1SPHK1GUSB | |
| SCHEMBL7569033 | 0.90 | — | — | |
| SCHEMBL21011949 | 0.88 | ALDH1A1 (0.44) | CYP1A2ALDH1A1GBA1SPHK1GUSB | |
| SCHEMBL22115680 | 0.86 | ALDH1A1 (0.36) | CYP1A2ALDH1A1GBA1SPHK1GUSB | |
| SCHEMBL4997191 | 0.86 | GBA1 (0.40) | GBA1SPHK1GUSBGLB1GBA2 | |
| SCHEMBL4859080 | 0.82 | GBA1 (0.32) | GBA1 | |
| SCHEMBL10642680 | 0.82 | — | — | |
| SCHEMBL29363158 | 0.79 | ALDH1A1 (0.50) | CYP1A2ALDH1A1GBA1SPHK1EPHX1 | |
| SCHEMBL9830506 | 0.79 | ALDH1A1 (0.41) | CYP1A2ALDH1A1GBA1SPHK1GUSB | |
| SCHEMBL19090078 | 0.79 | GLB1 (0.41) | CYP1A2ALDH1A1GBA1SPHK1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0494005-B1 | Multicomponent agent or kit for the preparation of the sulphoconjugated forms of pyridino-, pyrimidino- or triazino-N-oxyde compounds and method of application thereof | OREAL (FR) | 1997-02-05 | — | — | EP | claimed |
| US-5360804-A | STABILITY | L'OREAL (FR) | 1994-11-01 | — | — | US | claimed |
| EP-0494005-A1 | Multicomponent agent or kit for the preparation of the sulphoconjugated forms of pyridino-, pyrimidino- or triazino-N-oxyde compounds and method of application thereof | L'OREAL (FR) | 1992-07-08 | — | — | EP | claimed |
| US-20050049232-A1 | Composition | LINDAU PAR (SE) | 2005-03-03 | — | — | US | disclosed |
| EP-1463483-A1 | NEW COMPOSITION | Ponsus Pharma AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055454-A1 | NEW COMPOSITION | PONSUS PHARMA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| EP-0494005-B1 | Multicomponent agent or kit for the preparation of the sulphoconjugated forms of pyridino-, pyrimidino- or triazino-N-oxyde compounds and method of application thereof | OREAL (FR) | 1997-02-05 | — | — | EP | disclosed |
| US-5360804-A | STABILITY | L'OREAL (FR) | 1994-11-01 | — | — | US | disclosed |
| EP-0494005-A1 | Multicomponent agent or kit for the preparation of the sulphoconjugated forms of pyridino-, pyrimidino- or triazino-N-oxyde compounds and method of application thereof | L'OREAL (FR) | 1992-07-08 | — | — | EP | disclosed |
| US-4393065-A | INCREASED PRODUCTIVITY OF BY-PRODUCTS BY INCLUSION OF PYRIMIDINE COMPOUNDS | THE UPJOHN COMPANY (US) | 1983-07-12 | — | — | US | disclosed |
| US-4316901-A | Animal feed and process | THE UPJOHN COMPANY (US) | 1982-02-23 | — | — | US | disclosed |
| US-4308271-A | PYRIMIDINE OXIDE DERIVATIVES TO INCREASE PRODUCTION | THE UPJOHN COMPANY (US) | 1981-12-29 | — | — | US | disclosed |
| US-4307093-A | INCREASING PRODUCTION USING OXATRIAZINES | THE UPJOHN COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
| US-4282228-A | Animal feed and process | THE UPJOHN COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| US-4122264-A | Pyridine containing morpholines | THE UPJOHN COMPANY (US) | 1978-10-24 | — | — | US | disclosed |
| US-4115396-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4089672-A | HERBICIDES | THE UPJOHN COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-4084955-A | 1-CARBOXYALKYL-DI- AND TRIHALOPYRAZOLES, HERBICIDES | THE UPJOHN COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
| US-4067874-A | Novel pyridine 1-oxides | THE UPJOHN COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-3995035-A | 6-Amino-2-lower-alkyl-4-nitropyridine N-oxide compositions and coccidiostat process | THE UPJOHN COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049232-A1 | Composition | CUTA, LIPG, LIPA | CYP1A2 582/4885ALDH1A1 1751/4885GBA1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.